Review Article

Metabolic Syndrome, Obesity, and Gastrointestinal Cancer

Shintaro Fujihara, Hirohito Mori, Hideki Kobara, Noriko Nishiyama, Mitsuyoshi Kobayashi, Makoto Oryu, and Tsutomu Masaki

Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Takamatsu, Kagawa 761-0793, Japan

Correspondence should be addressed to Shintaro Fujihara, joshin@med.kagawa-u.ac.jp

Received 29 June 2012; Revised 18 November 2012; Accepted 18 November 2012

Academic Editor: Dan L. Dumitrascu

Copyright © 2012 Shintaro Fujihara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Metabolic syndrome is a cluster of metabolic abnormalities and is defined as the presence of three or more of the following factors: increased waist circumference, elevated triglycerides, low high-density lipoprotein (HDL) cholesterol, high blood pressure, and high fasting glucose. Obesity, which is accompanied by metabolic dysregulation often manifested in the metabolic syndrome, is an established risk factor for many cancers. Adipose tissue, particularly visceral fat, is an important metabolic tissue as it secretes systemic factors that alter the immunologic, metabolic, and endocrine milieu and also promotes insulin resistance. Within the growth-promoting, proinflammatory environment of the obese state, cross-talk between macrophages, adipocytes, and epithelial cells occurs via obesity-associated hormones, adipocytokines, and other mediators that may enhance cancer risk and progression. This paper synthesizes the evidence on key molecular mechanisms underlying the obesity-cancer link.

1. Introduction

The clustering of atherosclerotic risk factors that identify metabolic syndrome was first recognized in 1983 [1]. In 1988, Reaven [2] introduced the term syndrome X, in which insulin resistance (IR) was the common denominator. In 1998, the World Health Organization recommended a unifying definition and chose the term metabolic syndrome [3], primarily because the available data did not support IR as the cause of all of the components of this syndrome [4].

Metabolic syndrome is now recognized as a cluster of metabolic abnormalities and is defined as the presence of three or more of the following factors: abdominal obesity (increased waist circumference), elevated triglycerides, low high-density lipoprotein (HDL) cholesterol, high blood pressure, and high fasting glucose [5].

IR, along with its associated hyperinsulinemia and hyperglycemia, and adipocyte cytokines (adipokines) may lead to vascular endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular inflammation, all of which promote the development of atherosclerotic cardiovascular disease (CVD) [2, 6–8].

The metabolic syndrome involves a proinflammatory, prothrombotic state and is associated with elevated levels of C-reactive protein [9–12], interleukin (IL)-6 [12], and plasminogen activator inhibitor (PAI)-1 [13]. These inflammatory and prothrombotic markers are also associated with an increased risk for subsequent CVD and type 2 diabetes [11, 12].

In addition to the mechanical effects of obesity, such as an increase in intra-abdominal pressure caused by excess adipose tissue, adipose tissue secretes various adipokines, such as tumor necrosis factor (TNF), IL-6, leptin, and insulin-like growth factor-1 (IGF-1), which are considered to have pathogenic effects in relation to gastrointestinal cancer.

The classification of obesity for epidemiological purposes defines overweight as body mass index (BMI) >25 kg/m² and obesity as BMI >30 kg/m² [14]. Fat is principally deposited in two compartments—subcutaneous and central depots. It is thought that central fat (i.e., visceral fat) is more metabolically active than peripheral subcutaneous fat [15, 16].

In the Asian Cohort Consortium, the East Asian, Indian, and Bangladeshi populations with a BMI <20.1 kg/m² had
significantly higher mortality compared with subjects with a BMI of 22.6–25 kg/m² [17]. Mortality was lowest among men and women with a BMI in the range of 22.6–27.5 kg/m².

Omental adipose tissue, also referred to as visceral adipose tissue, can exert systemic effects that are putatively involved in cancer biology [18]. Metabolic syndrome is defined based on a cluster of abnormal clinical factors that have been associated with the development of CVD morbidity [19] and type 2 diabetes mellitus [20]. The definitions used in this paper are summarized in Table 1 [3, 5, 21–23].

Overall, 14% of all cancer deaths in men and 20% of all cancer deaths in women are attributable to overweight and obesity [29]. Obesity is associated with increased mortality arising from cancers of the prostate and stomach in men; of the breast (postmenopausal), endometrium, cervix, uterus, and ovaries in women; and of the kidney (renal cell), colon, esophagus (adenocarcinoma), pancreas, gallbladder, and liver in both sexes [29]. However, the relationship between metabolic syndrome and the pathogenesis of cancer is less well established.

Here, we review the association between metabolic syndrome and gastrointestinal cancer, focusing on the pathogenic roles of obesity and adipokines.

2. Epidemiology and Epigenetics of Obesity and Metabolic Syndrome

The prevalence of metabolic syndrome, as defined by the 2001 Adult Treatment Panel (ATP) III criteria, was evaluated in 8814 adults in the United States who participated in the third National Health and Nutrition Examination Survey (NHANES III, from 1988 to 1994) [30]. The overall prevalence was 22%, with an age-dependent increase (6.7, 43.5, and 42.0% for the age groups of 20–29, 60–69, and >70 years, respectively).

The prevalence of metabolic syndrome is steadily increasing. Indeed, in NHANES from 1999 to 2002, 34.5% of participants met the ATP III criteria for metabolic syndrome, an increase from 22% in NHANES III (from 1988 to 1994) [30, 31]. In addition, metabolic syndrome, defined by the ATP III criteria revised in 2005, was assessed in 3325 Framingham Heart Study participants, aged 22–81 years who did not have diabetes or CVD at a baseline examination in the early 1990s [32].

39% prevalence in moderately obese and 50% prevalence in severely obese children and adolescents, based on study of 439 obese children and adolescents; metabolic syndrome defined as 3 or more criteria for age and sex.

Epidemiological and animal studies have demonstrated a close link between maternal nutrition and chronic metabolic disease in children and adults [33]. For example, evidence supporting the effects of maternal malnutrition on the health of the offspring was presented in a historical cohort of Dutch individuals whose mothers were exposed to the wartime famine of 1944-1945. Of note, the offspring of women exposed to undernutrition during early pregnancy were more likely to develop metabolic syndrome in adulthood compared with offspring of women who were pregnant either before or after the famine [34].

The current evidence for the fetal influences on later health is mainly attributed to the mother’s diet, as maternal obesity, excessive weight gain during pregnancy, and gestational diabetes are known to increase the risk of various diseases in the offspring. Nutritional imbalance (over- or undernutrition) and exposure to environmental chemicals during development can also increase the risk of these diseases, possibly through common pathways [35].

These pathways include DNA methylation, histone modifications, and noncoding RNA expression. Such epigenetic modifications can be passed from one cell generation to the next and, in some cases, if germ cells are targeted, can be transmitted across generations [36].

Disruption of epigenetic mechanisms can result in oxidative stress, obesity, insulin resistance, diabetes, and vascular dysfunction in animals and humans. Hormones, cytokines, and nutritional components can directly activate receptors that stimulate gene expression and can also activate or inhibit the enzymes and pathways that are responsible for DNA methylation, chromatin remodeling, and noncoding RNAs, which ultimately control gene expression. Thus, epigenetic regulatory pathways are the likely targets that mediate the effects of nutrients and environmental toxins during development and potentially across the entire lifespan.

3. Mechanisms

Adipose tissue, particularly visceral fat [37], is an important metabolic tissue that secretes systemic factors that can alter the immunologic, metabolic, and endocrine milieu and promote insulin resistance. Adipose tissue is a metabolically active organ that secretes many adipokines, including TNF, IL-6, and adiponectin. It is also a major source of growth factors, such as IGF-1, which is also produced in the liver. Many of these adipokines can induce insulin resistance syndrome [38].

Within the growth-promoting, proinflammatory environment of the obese state, cross-talk between macrophages, adipocytes, and epithelial cells occurs via obesity-associated hormones, cytokines, and other mediators that may increase the risk of cancer and its progression [39].

3.1. Insulin and Insulin-Like Growth Factor. Obesity is strongly associated with insulin resistance, in which the levels of insulin and IGF-1 are elevated. Insulin can act as a mitogen and is associated with several cancers [40]. Insulin is an important growth factor for colonic mucosal cells and colonic carcinoma cells in vitro [41–43], while IGF-1 inhibits apoptosis and promotes cell cycle progression, leading to the development of cancer [44, 45].

Most research to date has focused on the systemic mechanisms underpinning the association between obesity and cancer. Potentially relevant pathways include the insulin-IGF axis, sex steroid pathways, and adipocytokine pathways.

Insulin is an anti-inflammatory agent, and anti-inflammatory agents have been shown to reduce the risk of
### Table 1: Definitions of metabolic syndrome.

| WHO [3] | IDF [2] | AHA/NHLBI [21] | ATP III [5] | Japanese consensus [22] |
|----------|---------|----------------|-------------|-------------------------|
| Abdominal obesity | WC: hip ratio ≥ 0.85 or BMI ≥ 30 kg/m² | WC and two or more risk factors | WC (102 cm (40 inches) or higher in men 88 cm (35 inches) or higher in women) | WC and two or more risk factors |
| Impaired glucose regulation or hyperinsulinemia and more than two factors | Fasting plasma ≥ 6.1 mmol/L or 2 h postglucose load ≥ 7.8 mmol/L | Fasting plasma ≥ 100 mg/dL (5.6 mmol/L) or previously diagnosed type 2 DM | Fasting plasma ≥ 100 mg/dL (5.6 mmol/L) or previously diagnosed type 2 DM | WC (102 cm (40 inches) or higher in men 88 cm (35 inches) or higher in women) |
| Hyperinsulinemia | Fasting serum insulin > 1/3rd quartile for control group | Not included | Not included | Not included |
| Triglycerides | ≥150 mg/dL (1.7 mmol/L) | ≥150 mg/dL (1.7 mmol/L) | ≥150 mg/dL (1.7 mmol/L) | ≥150 mg/dL (1.7 mmol/L) or treatment for same |
| HDL concentration | Not included | Men: <40 mg/dL (1.03 mmol/L) Women: <50 mg/dL (1.3 mmol/L) | Men: <40 mg/dL (1.03 mmol/L) Women: <50 mg/dL (1.3 mmol/L) | <40 mg/dL (1.03 mmol/L) |
| Hypertension | ≥140/90 mmHg | ≥130/≥80 mmHg or treatment for same | ≥130/≥85 mm Hg or treatment for same | ≥130/≥85 mm Hg or treatment for same |
| Microalbuminuria | Albumin/creatinine ratio > 30 mg/g | Not included | Not included | Not included |

WHO: World Health Organization; IDF: International Diabetes Federation; NHLBI: National Heart, Lung and Blood Institute; AHA: American Heart Association; World Heart Federation; ATP III: Adult Treatment Panel III, report of the National Cholesterol Education; WC: waist circumference; BMI: body mass index; DM: diabetes mellitus; HDL: high-density lipoprotein.
colorectal neoplasms [46, 47]. Therefore, the link between hyperinsulinemia and colorectal neoplasms is unclear.

Obesity is also associated with tissue inflammation, which is at least partly mediated by adipose tissue. It was speculated that subclinical inflammation is associated with the development of colorectal cancer [48] because chronic inflammation can result in colorectal cancer in patients with ulcerative colitis [49].

Therefore, one possible explanation for the link between diabetes and colorectal cancer is hyperinsulinemia. This link was proposed because insulin is an important growth factor for colonic mucosal cells and stimulates the proliferation of colonic tumor cells [41, 42, 50].

The plasma concentrations of IGF-1 and IGF binding protein-3 (IGFBP-3) were reported to influence the risk of colorectal cancer in a prospective cohort of 14,916 men [51]. Subjects with IGF-1 levels in the highest quintile were more likely to develop colorectal cancer compared with subjects with IGF-1 levels in the lowest quintile. By contrast, higher plasma IGFBP-3 levels were protective against colorectal cancer. A similar relationship between serum C-peptide levels (a marker for insulin production) and colorectal cancer risk was reported in the Physicians' Health Study, and this association was independent of IGF-1 and IGFBP-3 levels [52].

Genetic polymorphisms of IGF-1 may also increase the risk of cancer [53]. Polymorphisms of IGF-1 (rs1520220 and rs2195239) were reported to decrease the risk of disease recurrence in Japanese patients with gastric cancer who had undergone curative gastrectomy [54].

An earlier study [55] revealed that metformin, a commonly used oral antihyperglycemic agent belonging to the biguanide family, may reduce the risk of cancer, and improve its prognosis. One explanation for this finding is that metformin reduces the phosphorylation of epidermal growth factor receptor and IGF-1 receptor in vitro and in vivo [56].

3.2. Adipocytokines. Adipocyte-conditioned media can promote tumorigenesis in cancer cells by increasing cell proliferation, invasive potential, angiogenesis, and cross-talk between cancer cells and the surrounding extracellular matrix [45]. These actions are thought to be mediated by adipokines such as adiponectin, leptin, TNF, IL-6, IL-8, IL-10, and IL-1 receptor agonists [57].

Adiponectin is the most abundant adipocytokine and is predominantly secreted from visceral fat adipocytes. Adiponectin levels are inversely correlated with BMI [58] and are generally higher in women than in men. Adiponectin is an insulin sensitizer, with anti-angiogenic and antiinflammatory activities. It can also inhibit tumor growth in animals [59]. Adiponectin levels are also inversely correlated with the risk of gastric cancer [60]. Similarly, it may protect against liver tumorigenesis, as reduced adiponectin expression is associated with poor prognosis in obese patients with hepatocellular carcinoma (HCC) [61]. Additionally, visceral fat accumulation and decreased plasma adiponectin levels were associated with the development of colorectal adenoma in humans [62].

Mice with disruptions in the adiponectin gene are more likely to develop intestinal tumors, with decreased activation (i.e., phosphorylation) of AMP-activated protein kinase and increased PAI-1 levels compared with wild-type mice.

Several different molecular weight isoforms (i.e., high, medium, and low molecular weight adiponectin) can be detected in the vascular system. The biological effects of these isoforms are mainly mediated through two classical adiponectin receptor subtypes: AdipoR1 and AdipoR2 [63]. Several studies have examined the role of adiponectin receptors in the pathogenesis of colon cancer, yielding controversial results. In vitro, adiponectin suppressed colon cancer cell proliferation via AdipoR1- and AdipoR2-mediated AMPK activation [64]. In humans, the expression of adiponectin receptors was reported to be significantly higher [65] in areas occupied by colorectal tumors or similar [66] to that of normal colorectal tissue in individuals with colorectal cancer.

Leptin is an adipocyte-specific hormone that acts centrally to regulate appetite and bodyweight [67] and therefore acts as a signal for sufficient energy intake. Higher leptin levels are correlated with adiposity and are associated with colon cancer [68–70]. In vitro studies have confirmed that leptin promotes cell proliferation, angiogenesis, and metalloproteinase expression in esophageal and colon cancer cell lines [71].

Resistin, a 12.5-kDa protein encoded by a region on chromosome 19 in humans, is a 108 amino acid prepeptide [72]. In humans, resistin is mainly produced by peripheral blood mononuclear cells, macrophages, bone marrow, pancreatic cells, and adipocytes, as well as the spleen and muscles [73]. In the context of inflammation, resistin induces the expression and release of IL-1β, IL-6, IL-8, IL-12, TNF, and Toll-like-receptor-2 through the nuclear factor-κB pathway [74]. Resistin is also thought to mediate insulin resistance, although this effect appears to be limited to animals [74]. In humans, circulating resistin levels were greater in patients with colon cancer [75, 76] or colon adenoma [75] compared with control subjects. Resistin levels were not dependent on cancer stage, grade of dysplasia, or location [75]. In molecular-based studies, the resistin-related SNP C–420G genotype was associated with an increased risk of colorectal cancer (per allele odds ratio [OR] 1.18, 95% confidence interval [CI] 0.99–1.40) [134], whereas the resistin-promoter SNP C–180G was not associated with elevated resistin levels in patients with colon cancer [135].

3.3. Immunomodulation. Excess adipose tissue is associated with chronic, systemic, low-grade inflammation [77]. The amount of adipocytokines produced by adipose tissue is strongly influenced by the immune cells present in adipose tissue [78–80]. Adipose tissue in obese people shows extensive macrophage infiltration, the number of which is correlated with the level of adiposity [81].

The immune system plays a fundamental role in antitumor immunity, and, under certain circumstances, it can promote tumor development and progression. In most studies, the density of tumor-associated macrophages was
correlated with increased angiogenesis, tumor invasion, and poor prognosis [82].

4. Metabolic Syndrome and Gastrointestinal Cancer

4.1. Barrett’s Esophagus and Esophageal Adenocarcinoma. Gastroesophageal reflux disease (GERD) is a common cause of morbidity and healthcare use in many countries. A positive association between increased BMI and the presence of GERD was reported in the United States, but this relationship became apparent only after stratification by country and the level of BMI [83].

Overweight and high BMI are associated with an increased risk of esophageal adenocarcinoma and adenocarcinoma of the gastric cardia, even in subjects with a normal BMI [84–86]. In a meta-analysis of eight studies, the pooled adjusted ORs for esophageal adenocarcinoma among subjects with a BMI of 25–30 kg/m² or >30 kg/m² were 1.52 and 2.78, respectively [84].

Adipose tissues, particularly metabolically active visceral adipose tissues, produce large amounts of adipocytokines, including IL-6 and TNF [87], which may play a role in GERD or subsequent carcinogenesis. Leptin is predominantly secreted from adipose tissues, and its serum levels increase in proportion to body fat mass [88]. Leptin was reported to stimulate cell proliferation and inhibit apoptosis in Barrett’s-derived esophageal adenocarcinoma cells [89].

Obesity is also associated with upregulated leptin receptor and adiponectin receptor expression in esophageal adenocarcinoma cells. The association between leptin receptor- and adiponectin receptor expression with tumor stage suggests that adipocytokines may influence tumor biology. Over 90% of esophageal adenocarcinomas were reported to express the leptin receptor, with most (67%) showing markedly upregulated expression [90].

The systemic inflammatory state that develops as a consequence of disturbed metabolism in obese patients and the associated impact of adipocytokines and procoagulants released by adipocytes in visceral fat may underlie the relationship between obesity and esophageal adenocarcinoma [91].

Interestingly, subjects with serum insulin and IGF-1 levels in the highest tertiles had the highest risk of Barrett’s esophagus. Serum IGF-1 levels in the highest tertile were associated with an increased risk of Barrett’s esophagus (adjusted OR 4.05, 95% CI 2.01–8.17) compared with a control group who underwent screening colonoscopy, but were not significantly different from a control group of subjects with GERD [92].

4.2. Gastric Adenocarcinoma. Excess body weight and obesity are associated with an increased risk of gastric cancer [93]. For example, in a meta-analysis of cohort studies involving 9492 patients with gastric cancer, excess body weight (BMI 25–30 kg/m²) and obesity (BMI > 25 kg/m²) were associated with an increased risk of cancer of the gastric cardia among Asians and non-Asians, and with gastric cancer among non-Asians. The strength of these associations increased with increasing BMI. However, overweight was not an independent prognostic factor for long-term survival in Western patients with gastric cancer [94].

4.3. Colorectal Adenocarcinoma. Obesity is an important risk factor for colorectal cancer. Two large prospective cohort studies have shown that obesity increases the risk of colorectal cancer by approximately 1.5-fold compared with normal weight individuals (BMI 18.5–24.9 kg/m²) [95, 96]. Similarly, in a systematic review of data from 29 studies involving 37,334 patients, each 5 kg/m² increase in BMI was associated with a 24% increased incidence of colon and rectal cancer in men, and a 9% higher incidence of colon cancer in women [97].

Many studies have demonstrated that the association between obesity and colorectal cancer is stronger in men than in women. This was hypothesized to be due to differences in adipose tissue distribution, as the more pronounced visceral adiposity in men than in women mirrors the apparent difference in risk [98].

Colorectal cancer and adenoma disease are associated with dietary factors, such as red meat, high fat content, and inadequate fiber intake. Of note, high intake of red meat and processed meat was associated with increased risk of colorectal, colon, and rectal cancers [99, 100].

Two studies also found an increased risk of colorectal cancer in subjects with metabolic syndrome [25, 101]. Interestingly, in one of these studies, the risk was higher in men than in women [25].

It is also becoming apparent that adiposity is the factor that is most strongly associated with the risk of colorectal cancer [102]. Central obesity, triglyceride levels, and metabolic syndrome are all risk factors for colorectal adenoma, including advanced adenoma and multiplicity [103]. Metabolic syndrome was also associated with an increased risk of adenoma. This association between multiple syndrome and colorectal adenoma was observed regardless of advanced/low-risk adenoma and multiplicity [103].

4.4. HCC. Several epidemiologic studies have revealed a possible link between diabetes mellitus and HCC [17, 69, 104, 105]. However, the associations between diabetes and HCC should be interpreted with care. In many patients, glucose intolerance is secondary to the development of cirrhosis. Therefore, diabetes may be a surrogate for cirrhosis, which increases the risk of HCC. Many patients with diabetes also have nonalcoholic fatty liver disease (NAFLD), another risk factor for HCC. There is growing evidence that NAFLD represents an increasingly common underlying liver disease in patients with HCC [28, 106, 107]. It is likely that NAFLD causes HCC via cirrhosis, although the exact pathogenesis is unclear. Nevertheless, one study showed that HCC in patients with nonalcoholic steatohepatitis was associated with obesity, diabetes, hypertension, and male sex [107]. Unfortunately, very few studies have specifically examined the association between metabolic syndrome and cancer risk. The predominant manifestation of metabolic
Table 2: Metabolic syndrome and gastrointestinal disease.

| Reference                     | Year | Patients no. | Definitions of metabolic syndrome | Relative risk (RR) or odds ratios (OR) | P value |
|-------------------------------|------|--------------|-----------------------------------|---------------------------------------|---------|
| Pelucchi et al. [24]         | 2010 | 1378         | IDF criteria                      | Men: OR, 2.09 (95% CI, 1.38–3.18)      | <0.001  |
|                               |      |              | PDF criteria                      | Women: OR, 1.15 (95% CI, 0.68–1.94)    | P = 0.22|
| Colorectal cancer             |      |              | >3 components                     | Men: RR, 1.78 (95% CI, 1.0–3.6)        |         |
| Ahmed et al. [25]            | 2006 | 194          | ATP III                           | Women: RR, 1.16 (95% CI, 0.6–2.2)      |         |
| Nonalcoholic fatty liver disease |      | 816          | Presence of the metabolic syndrome | Men: OR, 4.00 (95% CI, 2.63–6.08)      | <0.001  |
| Hamaguchi et al. [26]        | 2005 | 816          | ATP III                           | Women: OR, 11.20 (95% CI, 4.85–25.87)  | <0.001  |
| liver fibrosis                |      |              | ATP III                           | OR, 3.5 (95% CI, 1.1–11.2)             | P = 0.032|
| NASH                          |      | 304          | ATP III                           | OR, 3.2 (95% CI, 1.2–8.9)              | P = 0.26|
| Hepatocellular carcinoma (HCC) |      | 304          | ATP III                           | OR, 2.13; (95% CI = 1.96–2.31)         | P < 0.0001|
| Intrahepatic cholangiocarcinoma |      | 3649         | ATP III                           | OR, 1.56; (95% CI = 1.32–1.83)         | P < 0.0001|

syndrome in the liver is NAFLD, which can progress to cirrhosis and ultimately HCC [108]. Interestingly, treatment with a thiazolidinedione or metformin was associated with a decreased risk of HCC in patients with diabetes [69].

4.5. Gallbladder and Biliary Carcinoma. An association between diabetes mellitus and cancer of the biliary tract was reported in several case-control and cohort studies. In a meta-analysis of 15 studies, patients with diabetes had a significantly higher risk of cholangiocarcinoma relative to individuals without diabetes [109]. A study of 743 patients with intrahepatic cholangiocarcinoma found that the presence of metabolic syndrome (defined by the presence of three of the following: elevated waist circumference/central obesity, dyslipidemia, hypertension, or impaired fasting glucose) was a risk factor for intrahepatic cholangiocarcinoma [110]. Therefore, it is unclear whether diabetes itself or other associated conditions (e.g., obesity and hyperlipidemia) are the major risk factors for cholangiocarcinoma.

4.6. Pancreatic Adenocarcinoma. Several studies have revealed a link between high body mass, lack of physical activity, and pancreatic cancer risk [111–117]. A BMI of ≥30 kg/m² was associated with a significantly increased risk of pancreatic cancer compared with a BMI of <23 kg/m². Height was also associated with an increased risk of pancreatic cancer. On the other hand, an inverse association was observed for moderate physical activity when comparing the highest and lowest categories, particularly among individuals with a BMI of ≥25 kg/m². It was also reported that high BMI is associated with decreased survival in patients with pancreatic cancer, although the mechanism for this association was not determined [118].

Other researchers have suggested that overweight and obese individuals develop pancreatic cancer at a younger age than do patients with a normal weight, and the rate and duration of survival are lower, once pancreatic cancer is diagnosed [115].

5. Conclusions

Metabolic syndrome represents a cluster of metabolic abnormalities and is defined as the presence of three or more of the following factors: abdominal obesity (i.e., increased waist circumference), elevated triglycerides, low HDL cholesterol, high blood pressure, and high fasting glucose. Multiple hormones, growth factors, cytokines, and other mediators associated with the obese state and metabolic syndrome enable cross-talk between macrophages, adipocytes, endothelial cells, and epithelial cells and therefore contribute to cancer-related processes. Efforts to increase our knowledge of the underlying mechanisms are crucial to help us design effective therapeutic strategies to prevent and treat metabolic abnormalities.

The association of gastrointestinal diseases with metabolic syndrome is summarized in Table 2. The incidence of cancer is clearly increased in obese individuals, but it is not yet clear whether weight loss can decrease the incidence of cancer [119].

Recent studies have shown that the risk of disease may be induced very early in the life course and it may be modifiable by nutrients. Consequently, it seems rational to improve nutrition and reduce exposure to environmental chemicals.
before and during pregnancy, and during the first few years of life. Such changes are likely to have a significant impact on reducing the disease burden and the associated healthcare costs.

References

[1] D. L. Wingard, E. Barrett Connor, M. H. Criqui, and L. Suarez, “Clustering of heart disease risk factors in diabetic compared to nondiabetic adults,” American Journal of Epidemiology, vol. 117, no. 1, pp. 19–26, 1983.

[2] G. M. Reaven, “Role of insulin resistance in human disease,” Diabetes, vol. 37, no. 12, pp. 1595–1607, 1988.

[3] K. G. Alberti, P. Z. Zimmet, and WHO Consultation, “Definition, diagnosis, and classification of diabetes mellitus and its complications—part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation,” Diabetes Medicine, vol. 15, pp. 539–553, 1998.

[4] B. Isomaa, P. Almgren, T. Tuomilehto et al., “Cardiovascular morbidity and mortality associated with the metabolic syndrome,” Diabetes Care, vol. 24, no. 4, pp. 683–689, 2001.

[5] J. I. Cleeman, “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001.

[6] R. A. DeFronzo and E. Ferrannini, “Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease,” Diabetes Care, vol. 14, no. 3, pp. 173–194, 1991.

[7] R. S. Lindsay and B. V. Howard, “Cardiovascular risk associated with the metabolic syndrome,” Current Diabetes Reports, vol. 4, no. 1, pp. 63–68, 2004.

[8] K. K. Koh, S. H. Han, and M. J. Quon, “Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions,” Journal of the American College of Cardiology, vol. 46, no. 11, pp. 1978–1985, 2005.

[9] P. M. Ridker, J. E. Buring, N. R. Cook, and N. Rifai, “C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women,” Circulation, vol. 107, no. 3, pp. 391–397, 2003.

[10] A. Festa, R. D’Agostino, G. Howard, L. Mykkänen, R. P. Tracy, and S. M. Haffner, “Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS),” Circulation, vol. 102, no. 1, pp. 42–47, 2000.

[11] P. M. Ridker, “Clinical application of C-reactive protein for cardiovascular disease detection and prevention,” Circulation, vol. 107, no. 3, pp. 365–369, 2003.

[12] A. D. Pradhan, J. E. Manson, N. Rifai, J. E. Buring, and P. M. Ridker, “C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus,” Journal of the American Medical Association, vol. 286, no. 3, pp. 327–334, 2001.

[13] A. Festa, R. D’Agostino, R. P. Tracy, and S. M. Haffner, “Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study,” Diabetes, vol. 51, no. 4, pp. 1131–1137, 2002.

[14] “Obesity: preventing and managing the global epidemic. Report of a WHO consultation,” World Health Organization Technical Report Series, vol. 894, pp. 1–253, 2000.

[15] E. E. Kershaw and J. S. Flier, “Adipose tissue as an endocrine organ,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2548–2556, 2004.

[16] M. C. Vohl, R. Sladek, J. Robitaille et al., “A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men,” Obesity Research, vol. 12, no. 8, pp. 1217–1222, 2004.

[17] W. Zheng, D. F. McLerran, B. Rolland et al., “Association between body-mass index and risk of death in more than 1 million Asians,” New England Journal of Medicine, vol. 364, no. 8, pp. 719–729, 2011.

[18] R. C. M. Van Kruisjijk, E. Van Der Wall, and F. L. J. Visseren, “Obesity and cancer: the role of dysfunctional adipose tissue,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 10, pp. 2569–2578, 2009.

[19] A. S. Gami, B. J. Witt, D. E. Howard et al., “Metabolic syndrome and risk of incident cardiovascular events and death. A systematic review and meta-analysis of longitudinal studies,” Journal of the American College of Cardiology, vol. 49, no. 4, pp. 403–414, 2007.

[20] E. S. Ford, “Prevalence of the metabolic syndrome defined by the international diabetes federation among adults in the U.S.,” Diabetes Care, vol. 28, no. 11, pp. 2745–2749, 2005.

[21] S. M. Grundy, J. I. Cleeman, S. R. Daniels et al., “Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement,” Circulation, vol. 112, no. 17, pp. 2735–2752, 2005.

[22] The Examination Committee of the Criteria for Metabolic Syndrome in Japan, “Definition and criteria of the metabolic syndrome in Japan,” Japan Internal Medicine, vol. 94, pp. 188–201, 2005 (Japanese).

[23] International Diabetes Federation, “The IDF Consensus Worldwide Definition of the Metabolic Syndrome,” International Diabetes Federation, Belgium, Brussels, 2006.

[24] C. Pelucchi, E. Negri, R. Talamini et al., “Metabolic syndrome is associated with colorectal cancer in men,” European Journal of Cancer, vol. 46, no. 10, pp. 1866–1872, 2010.

[25] R. L. Ahmed, K. H. Schmitz, K. E. Anderson, W. D. Rosamond, and A. R. Folsom, “The metabolic syndrome and risk of incident colorectal cancer,” Cancer, vol. 107, no. 1, pp. 28–36, 2006.

[26] M. Hamaguchi, T. Kojima, N. Takeda et al., “The metabolic syndrome as a predictor of nonalcoholic fatty liver disease,” Annals of Internal Medicine, vol. 143, no. 10, pp. 722–730, 2005.

[27] G. Marchesini, E. Bugianesi, G. Forlani et al., “Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome,” Hepatology, vol. 37, no. 4, pp. 917–923, 2003.

[28] T. M. Welzel, B. I. Graubard, S. Zeuzem, H. B. El-Serag, J. A. Davila, and K. A. Mcglyn, “Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-medicare database,” Hepatology, vol. 54, no. 2, pp. 463–471, 2011.

[29] E. E. Calle, C. Rodriguez, K. Walker-Thurmond, and M. J. Thun, “Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults,” New England Journal of Medicine, vol. 348, no. 17, pp. 1625–1638, 2003.

[30] E. S. Ford, W. H. Giles, and W. H. Dietz, “Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey,” Journal of the American Medical Association, vol. 287, no. 3, pp. 356–359, 2002.
[31] E. S. Ford, “Prevalence of the metabolic syndrome defined by the international diabetes federation among adults in the U.S.,” *Diabetes Care*, vol. 28, no. 11, pp. 2745–2749, 2005.

[32] P. W. F. Wilson, R. B. D’Agostino, H. Parise, L. Sullivan, and J. B. Meigs, “Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus,” *Circulation*, vol. 112, no. 20, pp. 3066–3072, 2005.

[33] C. Invitti, L. Gilardini, G. Viberti et al., “Obesity and the metabolic syndrome in children and adolescents,” *New England Journal of Medicine*, vol. 351, no. 11, pp. 1146–1148, 2004.

[34] T. J. Roseboom, J. H. P. Van der Meulen, A. C. J. Ravelli, C. Osmond, D. J. P. Barker, and O. P. Bleker, “Effects of prenatal exposure to the Dutch famine on adult disease in later life: an overview,” *Twin Research*, vol. 185, no. 1-2, pp. 93–98, 2001.

[35] R. Barouki, P. D. Gluckman, and P. Grandjean, “Developmental origins of non-communicable disease: implications for research and public health,” *Environmental Health*, vol. 11, pp. 42, 2012.

[36] M. K. Skinner, M. Manikkam, and C. Guerrero-Bosagna, “Epigenetic transgenerational actions of endocrine disruptors,” *Reproductive Toxicology*, vol. 31, no. 3, pp. 337–343, 2011.

[37] B. L. Wajchenberg, “Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome,” *Endocrine Reviews*, vol. 21, no. 6, pp. 697–738, 2000.

[38] B. J. John, S. Irukulla, A. M. Abulafi, D. Kumar, and M. A. Mendall, “Systematic review: adipose tissue, obesity and gastrointestinal diseases,” *Alimentary Pharmacology and Therapeutics*, vol. 23, no. 11, pp. 1511–1523, 2006.

[39] S. D. Hursting and M. J. Hursting, “Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer,” *Atherosclerosis, Thrombosis, and Vascular Biology*, vol. 32, pp. 1766–1770, 2012.

[40] J. M. Argilés and F. J. López-Soriano, “Insulin and cancer,” *International Journal of Oncology*, vol. 18, no. 4, pp. 683–687, 2001.

[41] L. F. Watkins, L. R. Lewis, and A. E. Levine, “Characterization of the synergistic effect of insulin and transferrin and the regulation of their receptors on a human colon carcinoma cell line,” *International Journal of Cancer*, vol. 45, no. 2, pp. 372–375, 1990.

[42] M. Koenuma, T. Yamori, and T. Tsuruo, “Insulin and insulin-like growth factor 1 stimulate proliferation of metastatic variants of colon carcinoma 26,” *Japanese Journal of Cancer Research*, vol. 80, no. 1, pp. 51–58, 1989.

[43] J. Bjork, J. Nilsson, R. Hultcrantz, and C. Johansson, “Growth-regulatory effects of sensory neuropeptides, epidermal growth factor, insulin, and somatostatin on the non-transformed intestinal epithelial cell line IEC-6 and the colon cancer cell line HT29,” *Scandinavian Journal of Gastroenterology*, vol. 28, no. 10, pp. 879–884, 1993.

[44] R. Kaaks and A. Lukanova, “Energy balance and cancer: the role of insulin and insulin-like growth factor-I,” *Proceedings of the Nutrition Society*, vol. 60, no. 1, pp. 91–106, 2001.

[45] S. A. Aaronson, “Growth factors and cancer,” *Science*, vol. 254, no. 5035, pp. 1146–1153, 1991.

[46] M. V. Grau, J. R. Rees, and J. A. Baron, “Chemoprevention in gastrointestinal cancers: current status,” *Basic and Clinical Pharmacology and Toxicology*, vol. 98, no. 3, pp. 281–287, 2006.

[47] E. Giovannucci, E. B. Rimm, M. J. Stampfer, G. A. Colditz, A. Ascherio, and W. C. Willett, “Aspirin use and the risk for colorectal cancer and adenoma in male health professionals,” *Annals of Internal Medicine*, vol. 121, no. 4, pp. 241–246, 1994.

[48] A. Poullis, R. Foster, A. Shetty, M. K. Fagerhol, and M. A. Mendall, “Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk,” *Cancer Epidemiology Biomarkers and Prevention*, vol. 13, no. 2, pp. 279–284, 2004.

[49] T. Kadowaki, K. Har, T. Yamauchi, Y. Terauchi, K. Tober, and R. Nagai, “Molecular mechanism of insulin resistance and obesity,” *Experimental Biology and Medicine*, vol. 228, no. 10, pp. 1111–1117, 2003.

[50] E. Giovannucci, “Insulin and colon cancer,” *Cancer Causes and Control*, vol. 6, no. 2, pp. 164–179, 1995.

[51] J. Ma, M. N. Pollak, E. Giovannucci et al., “Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3,” *Journal of the National Cancer Institute*, vol. 91, no. 7, pp. 620–625, 1999.

[52] J. Ma, E. Giovannucci, M. Pollak et al., “A prospective study of plasma C-peptide and colorectal cancer risk in men,” *Journal of the National Cancer Institute*, vol. 96, no. 7, pp. 546–553, 2004.

[53] D. Ennishi, K. Shitara, H. Ito et al., “Association between insulin-like growth factor-1 polymorphisms and stomach cancer risk in a Japanese population,” *Cancer Science*, vol. 102, no. 12, pp. 2231–2235, 2011.

[54] K. Shitara, S. Ito, K. Misawa et al., “Genetic polymorphism of IGF-1 predicts recurrence in patients with gastric cancer who have undergone curative gastrectomy,” *Annals of Oncology*, vol. 23, no. 3, pp. 659–664, 2012.

[55] M. B. Schneider, H. Matsuuzaki, J. Haorah et al., “Prevention of pancreatic cancer induction in hamsters by metformin,” *Gastroenterology*, vol. 120, no. 5, pp. 1263–1270, 2001.

[56] K. Kato, J. Gong, and H. Iwama, “The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo,” *Molecular Cancer Therapeutics*, vol. 11, no. 3, pp. 549–560, 2012.

[57] H. Tilg and A. R. Moschen, “Adipocytokines: mediators linking adipose tissue, inflammation and immunity,” *Nature Reviews Immunology*, vol. 6, no. 10, pp. 772–783, 2006.

[58] T. Kadowaki and T. Yamauchi, “Adiponectin and adiponectin receptors,” *Endocrine Reviews*, vol. 26, no. 3, pp. 439–451, 2005.

[59] D. P. Rose, D. Komninou, and G. D. Stephenson, “Obesity, adipocytokines, and insulin resistance in breast cancer,” *Obesity Reviews*, vol. 5, no. 3, pp. 153–165, 2004.

[60] M. Ishikawa, J. Kitayama, S. Kazama, T. Hiramatsu, K. Hatano, and H. Nagawa, “Plasma adiponectin and gastric cancer,” *Clinical Cancer Research*, vol. 11, no. 2 I, pp. 466–472, 2005.

[61] N. K. Saxena, P. P. Fu, A. Nagalingam et al., “Adiponectin modulates C-Jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma,” *Gastroenterology*, vol. 139, no. 5, pp. 1762–1773, 2010.

[62] M. Mutoli, N. Teraoka, S. Takasu et al., “Loss of adiponectin promotes intestinal carcinogenesis in mice and wild-type mice,” *Gastroenterology*, vol. 140, no. 7, pp. 2000–2008, 2011.

[63] T. Kadowaki, T. Yamauchi, N. Kubota, K. Hara, K. Ueki, and K. Tober, “Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome,” *Journal of Clinical Investigation*, vol. 116, no. 7, pp. 1784–1792, 2006.

[64] A. Y. Kim, Y. S. Lee, K. H. Kim et al., “Adiponectin represses colon cancer cell proliferation via AdipoR1- and...
-R2-mediated AMPK activation,” Molecular Endocrinology, vol. 24, no. 7, pp. 1441–1452, 2010.

[65] D. Barb, C. J. Williams, A. K. Neuworth, and C. S. Mantzoros, “Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence,” The American Journal of Clinical Nutrition, vol. 86, no. 3, pp. s858–s866, 2007.

[66] K. Yoneda, A. Tomimoto, H. Endo et al., “Expression of adiponectin receptors, AdipoR1 and AdipoR2, in normal colon epithelium and colon cancer tissue,” Oncology Reports, vol. 20, no. 3, pp. 479–483, 2008.

[67] D. E. Cummings and K. E. Foster, “Ghrelin-Leptin tango in body-weight regulation,” Gastroenterology, vol. 124, no. 5, pp. 1532–1535, 2003.

[68] P. Statin, R. Palmqvist, S. Söderberg et al., “Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden,” Oncology Reports, vol. 10, no. 6, pp. 2015–2021, 2003.

[69] P. Statin, A. Lukanova, C. Biessy et al., “Obesity and colon cancer: does leptin provide a link?” International Journal of Cancer, vol. 109, no. 1, pp. 149–152, 2004.

[70] H. Endo, K. Hosono, T. Uchiyama et al., “Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis,” Gut, vol. 60, no. 10, pp. 1363–1371, 2011.

[71] P. Somasundar, D. W. McFadden, S. M. Hileman, and L. Von-Lachow, “Leptin is a growth factor in cancer,” Journal of Surgical Research, vol. 116, no. 2, pp. 337–349, 2004.

[72] U. Meier and A. M. Gressner, “Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin,” Clinical Chemistry, vol. 50, no. 9, pp. 1511–1525, 2004.

[73] C. M. Kusminski, P. G. McKernan, and S. Kumar, “Role of resistin in obesity, insulin resistance and Type II diabetes,” Clinical Science, vol. 109, no. 3, pp. 243–256, 2005.

[74] S. E. Wozniak, L. L. Gee, M. S. Wachtel, and E. E. Frezza, “Adipose tissue: the new endocrine organ? a review article,” Digestive Diseases and Sciences, vol. 54, no. 9, pp. 1847–1856, 2009.

[75] C. M. Steppan and M. A. Lazar, “The current biology of resistin,” Journal of Internal Medicine, vol. 255, no. 4, pp. 439–447, 2004.

[76] G. Gonullu, H. Kahraman, A. Bedir, A. Bektas, and I. Yücel, “Association between adiponectin, resistin, insulin resistance, and colorectal tumors,” International Journal of Colorectal Disease, vol. 25, no. 2, pp. 205–212, 2010.

[77] U. N. Das, “Is obesity an inflammatory condition?” Nutrition, vol. 17, no. 11-12, pp. 953–966, 2001.

[78] A. Schäffer, U. Müller-Ladner, J. Schölmerich, and C. Büchler, “Role of adipose tissue as an inflammatory organ in human diseases,” Endocrine Reviews, vol. 27, no. 5, pp. 449–467, 2006.

[79] H. Xu, G. T. Barnes, Q. Yang et al., “Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1821–1830, 2003.

[80] S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante, “Obesity is associated with macrophage accumulation in adipose tissue,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, 2003.

[81] J. G. Neels and J. M. Olefsky, “Inflamed fat: what starts the fire?” Journal of Clinical Investigation, vol. 116, no. 1, pp. 33–35, 2005.

[82] E. Balkwill, “Cancer and the chemokine network,” Nature Reviews Cancer, vol. 4, no. 7, pp. 540–550, 2004.

[83] D. A. Corley and A. Kubo, “Body mass index and gastrointestinal reflux disease: a systematic review and meta-analysis,” American Journal of Gastroenterology, vol. 101, no. 11, pp. 2619–2628, 2006.

[84] H. Hampel, N. S. Abraham, and H. B. El-Serag, “Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications,” Annals of Internal Medicine, vol. 143, no. 3, pp. 199–211, 2005.

[85] C. C. Abnet, N. D. Freedman, A. R. Hollenbeck, J. F. Fraumeni, M. Leitzmann, and A. Schatzkin, “A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma,” European Journal of Cancer, vol. 44, no. 3, pp. 465–471, 2008.

[86] A. Kubo and D. A. Corley, “Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 5, pp. 872–878, 2006.

[87] K. John, S. Irukulla, A. M. Abulafi, D. Kumar, and M. A. Mendall, “Systematic review: adipose tissue, obesity and gastrointestinal diseases,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 11, pp. 1511–1523, 2006.

[88] N. H. Considine, M. K. Sinha, M. L. Heiman et al., “Serum immunoreactive-leptin concentrations in normal-weight and obese humans,” New England Journal of Medicine, vol. 334, no. 5, pp. 292–295, 1996.

[89] L. N. Harris, P. A. B. Blyth, G. Mutungi, and I. L. P. Beales, “Leptin stimulates proliferation and inhibits apoptosis in Barrett’s esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation,” Endocrinology, vol. 147, no. 9, pp. 4505–4516, 2006.

[90] J. M. Howard, P. Beddy, D. Ennis, M. Keogan, G. P. Pidgeon, and J. V. Reynolds, “Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma,” British Journal of Surgery, vol. 97, no. 7, pp. 1020–1027, 2010.

[91] A. M. Ryan, M. Duong, L. Healy et al., “Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets,” Cancer Epidemiology, vol. 35, no. 4, pp. 309–319, 2011.

[92] K. B. Greer, C. L. Thompson, L. Brenner et al., “Association of insulin and insulin-like growth factors with Barrett’s oesophagus,” Gut, vol. 61, no. 5, pp. 665–672, 2012.

[93] P. Yang, Y. Zhou, B. Chen et al., “Overweight, obesity and colorectal cancer risk: results from a meta-analysis of cohort studies,” European Journal of Cancer, vol. 45, no. 16, pp. 2867–2873, 2009.

[94] J. Kulig, M. Sierzga, P. Koldziejczyk et al., “Implications of overweight in gastric cancer: a multicenter study in a Western patient population,” European Journal of Surgical Oncology, vol. 36, no. 10, pp. 969–976, 2010.

[95] T. Mizoue, M. Inoue, K. Waki et al., “Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies,” American Journal of Epidemiology, vol. 167, no. 12, pp. 1397–1406, 2008.

[96] L. Harnack, D. R. Jacobs Jr., K. Nicodemus, D. Lazovich, K. Anderson, and A. R. Folsom, “Relationship of folate, vitamin B-6, vitamin B-12, and methionine intake to incidence of colorectal cancers,” Nutrition and Cancer, vol. 43, no. 2, pp. 152–158, 2002.

[97] E. Giovannucci, E. B. Rimm, A. Ascherio, M. J. Stampfer, G. A. Colditz, and W. C. Willett, “Alcohol, low-methionine-low-folate diets, and risk of colon cancer in men,” Journal of the National Cancer Institute, vol. 87, no. 4, pp. 265–273, 1995.
